Uncategorized Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health by Mbio2018|Published September 1, 2018 https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
Published May 15, 2023 Manhattan BioSolutions, Inc. Enters into License Option Agreement with Wisconsin Alumni Research Foundation (WARF) for the RNA Nuclease Technology
Published January 30, 2025 Manhattan BioSolutions Initiates NCI PIVOT Collaboration in Pediatric Cancers
Published November 1, 2018 Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City
Published May 8, 2025 Manhattan BioSolutions’ TxD ADC Collaboration Secures REACH Award from the New York Center for Biotechnology at the Stony Brook University
